Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation.

Ann Pharmacother

Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.

Published: January 2008

Objective: To evaluate the safety and efficacy of early initiation of inhibitors of the renin-angiotensin-aldosterone system (RAAS) in renal transplant patients.

Data Sources: A literature search was conducted using MEDLINE (1950-September 2007), PubMed (1966-September 2007), and International Pharmaceutical Abstracts (1970-September 2007) with combinations of the following terms: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II type 1 receptor blockers (ARBs), and kidney transplant. Articles obtained from this search were cross-referenced and bibliographies were checked for all relevant information.

Study Selection And Data Extraction: All articles that examined the early (within 12 wk) initiation of either an ACE inhibitor or an ARB in renal transplant patients were included.

Data Synthesis: A search of the literature revealed 7 studies that had examined the safety or efficacy of early use of ACE inhibitors and ARBs in posttransplant patients. One study examined only plasma levels of a common marker for tissue fibrosis and one included only patients who had early graft dysfunction. Of the other 5 studies, 3 primarily reported safety endpoints and 2 reported clinical efficacy endpoints. Safety data in patients with functioning grafts (serum creatinine ranged from <2.5 to 3.0 mg/dL) show that early therapy with inhibitors of the RAAS did not result in appreciable increases in serum creatinine or potassium levels after up to 9 months of therapy. Results from the efficacy trials indicate that early initiation of an ACE inhibitor may be more effective than a beta-blocker in reducing left ventricular hypertrophy and proteinuria after 24 months of treatment.

Conclusions: It appears that the early initiation of RAAS inhibitors is safe in posttransplant patients with functioning grafts. It is reasonable to consider these agents as first-line pharmacotherapy in patients with hypertension and compelling indications (ie, diabetes or heart failure) in the first 12 weeks following transplant. Data are insufficient to recommend these drugs in patients with early graft dysfunction.

Download full-text PDF

Source
http://dx.doi.org/10.1345/aph.1K471DOI Listing

Publication Analysis

Top Keywords

renin-angiotensin-aldosterone system
8
safety efficacy
8
efficacy early
8
early initiation
8
renal transplant
8
ace inhibitors
8
inhibitors
4
system inhibitors
4
inhibitors twelve
4
twelve weeks
4

Similar Publications

[Disease burden and clinical status of congenital heart disease combined with heart failure in China: a survey and analysis].

Zhonghua Er Ke Za Zhi

January 2025

Department of Cardiology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Key Laboratory of Children's Important Organ Development and Diseases of Chongqing Municipal Health Commission, National Clinical Key Cardiovascular Specialty, Chongqing400014, China.

To investigate the disease burden, clinical characteristics and independent risk factors affecting in-hospital outcomes of children with congenital heart disease (CHD) combined with heart failure (HF) in China. (1) Descriptive study: based on the global burden of disease study 2021, available data on children under 15 years of age with CHD and HF in China from 1990 to 2021 were collected. The prevalence and trends in different age subgroups (<1 year, 1-<2 years, 2-<5 years, 5-<10 years, 10-<15 years) were analyzed, and the annual percentage change (EAPC) was estimated using linear regression.

View Article and Find Full Text PDF

Association studies of vasoactive genes and preeclampsia in taiwan.

Placenta

January 2025

Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan City, Taiwan. Electronic address:

Background: Preeclampsia (PE) is a serious condition characterized by hypertension and proteinuria after 20 weeks of gestation. The exact cause of PE is unknown but may involve abnormalities in the renin-angiotensin-aldosterone system (RAAS) and endothelial nitric oxide synthase (eNOS). Genetic variations in angiotensinogen (AGT), angiotensin-converting enzyme (ACE), and eNOS genes have been associated with PE.

View Article and Find Full Text PDF

Chronic kidney disease (CKD) attributed to diabetes, termed diabetic kidney disease (DKD), is increasing with the rising global prevalence of diabetes. Patterns of DKD onset and progression have shifted in recent years because of population aging and advances in the treatment of diabetes. Prevention of the onset and progression of micro/macro-albuminuria is possible through comprehensive and strict management of lifestyle, blood glucose, blood pressure, and lipids in people with diabetes and early DKD.

View Article and Find Full Text PDF

Angiotensin receptor-neprilysin inhibitors (ARNIs) represent a novel class of medications characterized by their dual action on major cardiorenal regulators, specifically the renin-angiotensin system (RAS) and the natriuretic peptide (NP) system. Sacubitril/valsartan, a pioneering ARNI, has demonstrated strong antihypertensive effect as well as superior efficacy in preserving renal function compared to RAS inhibitors in heart failure patients with reduced ejection fraction. Here, we gathered evidence on the impact of sacubitril/valsartan on the preservation of kidney function in patients with cardiorenal syndrome (CRS).

View Article and Find Full Text PDF

Introduction: Hypertension is a chronic medical state and a major determining factor for cardiovascular and renal diseases. Both genetic and non-genetic factors contribute to hypertensive conditions among individuals. The renin-angiotensin-aldosterone system (RAAS) is a major genetic target for the anti-hypertension approach.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!